Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Catumaxomab in Non-muscle Invasive Bladder Cancer (NMIBC)
NCT04819399Phase 1Completed
- Sponsor
- Lindis Biotech GmbH
- Start
- Jul 2020
- Primary completion
- Aug 2025
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of catumaxomab in non-muscle-invasive bladder cancer (NMIBC), sponsored by Lindis Biotech GmbH. Primary endpoints: Dose Limiting Toxicity incidence at 1 year and Incidence and severity of treatment related adverse events at 2.5 years. Started Jul 2020; status: completed.
02
Drugs
catumaxomab
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT04819399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04819399.